{"schema_version":"secwatch.filing_event.v1","accession":"0001628908-24-000089","form_type":"8-K","ticker":"EVH","cik":"0001628908","company_name":"Evolent Health, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.865386+00:00","generated_at":"2026-05-31T10:57:47.506842+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolent Q2 revenue $647M (+38% YoY); net loss narrows to $6.4M; Adj. EBITDA $52M; narrows FY outlook","bullets":["Revenue $647.1M, up 37.9% YoY from $469.1M; net loss $(6.4)M vs $(41.4)M loss in Q2 2023.","Adjusted EBITDA $52.0M (8.0% margin) vs $47.4M (10.1% margin) in prior year.","Narrows full-year 2024 revenue outlook and updates Adjusted EBITDA guidance; reaffirms $300M exit run rate target.","Performance Suite average lives grew to 6,901 from 3,810 YoY; signed new oncology and specialty deals."],"urls":{"canonical":"https://secwatch.observer/filing/0001628908-24-000089","json":"https://secwatch.observer/filing/0001628908-24-000089.json","markdown":"https://secwatch.observer/filing/0001628908-24-000089.md","text":"https://secwatch.observer/filing/0001628908-24-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000089/0001628908-24-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000089/evh-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:57:47.506842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}